Moderna and Pfizer shares climbed, after the U.S. Food & Drug Administration authorized the use of a second shot of Covid boosters developed by the pharma companies.
According to the FDA, adults over the age of 50, as well as those with compromised immune systems, can receive a booster dose of either the Pfizer or Moderna vaccine at least four months after receiving the first.
Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, mentioned that current evidence suggests some waning of protection over time against serious outcomes from COVID-19 in older and immunocompromised individuals. Marks said that a second booster dose of either the Pfizer-BioNTech or Moderna COVID-19 vaccine could help increase protection levels for these higher-risk individuals. He also said that data revealed that an initial booster dose is critical in boosting protection for all adults from the potentially severe outcomes of COVID-19. “So, those who have not received their initial booster dose are strongly encouraged to do so,”Marks added.
The 50-day moving average for MRNA moved above the 200-day moving average on April 09, 2024. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
The Momentum Indicator moved above the 0 level on April 26, 2024. You may want to consider a long position or call options on MRNA as a result. In of 73 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for MRNA just turned positive on April 24, 2024. Looking at past instances where MRNA's MACD turned positive, the stock continued to rise in of 41 cases over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where MRNA advanced for three days, in of 284 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 217 cases where MRNA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRNA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
MRNA broke above its upper Bollinger Band on May 02, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MRNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.737) is normal, around the industry mean (10.278). P/E Ratio (0.000) is within average values for comparable stocks, (117.497). MRNA's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.470). MRNA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.015). P/S Ratio (9.372) is also within normal values, averaging (228.315).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of transformative medicines for patients
Industry Biotechnology